Literature DB >> 30249789

A53T Mutant Alpha-Synuclein Induces Tau-Dependent Postsynaptic Impairment Independently of Neurodegenerative Changes.

Peter J Teravskis1,2, Ana Covelo1, Eric C Miller3,1, Balvindar Singh3,1,2, Héctor A Martell-Martínez1, Michael A Benneyworth1, Christopher Gallardo4, Breeta R Oxnard1, Alfonso Araque1, Michael K Lee5,4,6,7, Dezhi Liao5,6.   

Abstract

Abnormalities in α-synuclein are implicated in the pathogenesis of Parkinson's disease (PD). Because α-synuclein is highly concentrated within presynaptic terminals, presynaptic dysfunction has been proposed as a potential pathogenic mechanism. Here, we report novel, tau-dependent, postsynaptic deficits caused by A53T mutant α-synuclein, which is linked to familial PD. We analyzed synaptic activity in hippocampal slices and cultured hippocampal neurons from transgenic mice of either sex expressing human WT, A53T, and A30P α-synuclein. Increased α-synuclein expression leads to decreased spontaneous synaptic vesicle release regardless of genotype. However, only those neurons expressing A53T α-synuclein exhibit postsynaptic dysfunction, including decreased miniature postsynaptic current amplitude and decreased AMPA to NMDA receptor current ratio. We also found that long-term potentiation and spatial learning were impaired by A53T α-synuclein expression. Mechanistically, postsynaptic dysfunction requires glycogen synthase kinase 3β-mediated tau phosphorylation, tau mislocalization to dendritic spines, and calcineurin-dependent AMPA receptor internalization. Previous studies reveal that human A53T α-synuclein has a high aggregation potential, which may explain the mutation's unique capacity to induce postsynaptic deficits. However, patients with sporadic PD with severe tau pathology are also more likely to have early onset cognitive decline. Our results here show a novel, functional role for tau: mediating the effects of α-synuclein on postsynaptic signaling. Therefore, the unraveled tau-mediated signaling cascade may contribute to the pathogenesis of dementia in A53T α-synuclein-linked familial PD cases, as well as some subgroups of PD cases with extensive tau pathology.SIGNIFICANCE STATEMENT Here, we report mutation-specific postsynaptic deficits that are caused by A53T mutant α-synuclein, which is linked to familial Parkinson's disease (PD). The overexpression of WT, A53T, or A30P human α-synuclein leads to decreased spontaneous synaptic vesicle release. However, only those neurons expressing A53T α-synuclein exhibit tau phosphorylation-dependent postsynaptic dysfunction, which is characterized by decreased miniature postsynaptic current amplitude and decreased AMPA to NMDA receptor current ratio. The mutation-specific postsynaptic effects caused by human A53T α-synuclein will help us better understand the neurobiological basis of this specific form of familial PD. The differential effects of exogenous human WT, A53T, A30P, and E46K α-synuclein on glutamatergic synaptic responses will help to explain the clinical heterogeneity of sporadic and familial PD.
Copyright © 2018 the authors 0270-6474/18/389755-14$15.00/0.

Entities:  

Keywords:  AMPA receptor; Parkinson's disease; frontotemporal dementia; synaptic plasticity; synuclein; tau

Mesh:

Substances:

Year:  2018        PMID: 30249789      PMCID: PMC6222065          DOI: 10.1523/JNEUROSCI.0344-18.2018

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  52 in total

1.  Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system.

Authors:  A Abeliovich; Y Schmitz; I Fariñas; D Choi-Lundberg; W H Ho; P E Castillo; N Shinsky; J M Verdugo; M Armanini; A Ryan; M Hynes; H Phillips; D Sulzer; A Rosenthal
Journal:  Neuron       Date:  2000-01       Impact factor: 17.173

2.  Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication.

Authors:  J Fuchs; C Nilsson; J Kachergus; M Munz; E-M Larsson; B Schüle; J W Langston; F A Middleton; O A Ross; M Hulihan; T Gasser; M J Farrer
Journal:  Neurology       Date:  2007-01-24       Impact factor: 9.910

Review 3.  Glutamate receptor dynamics in dendritic microdomains.

Authors:  Thomas M Newpher; Michael D Ehlers
Journal:  Neuron       Date:  2008-05-22       Impact factor: 17.173

4.  Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.

Authors:  David J Irwin; Murray Grossman; Daniel Weintraub; Howard I Hurtig; John E Duda; Sharon X Xie; Edward B Lee; Vivianna M Van Deerlin; Oscar L Lopez; Julia K Kofler; Peter T Nelson; Gregory A Jicha; Randy Woltjer; Joseph F Quinn; Jeffery Kaye; James B Leverenz; Debby Tsuang; Katelan Longfellow; Dora Yearout; Walter Kukull; C Dirk Keene; Thomas J Montine; Cyrus P Zabetian; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2017-01       Impact factor: 44.182

5.  Activation of postsynaptically silent synapses during pairing-induced LTP in CA1 region of hippocampal slice.

Authors:  D Liao; N A Hessler; R Malinow
Journal:  Nature       Date:  1995-06-01       Impact factor: 49.962

6.  Early-onset parkinsonism caused by alpha-synuclein gene triplication: Clinical and genetic findings in a novel family.

Authors:  Simone Olgiati; Astrid Thomas; Marialuisa Quadri; Guido J Breedveld; Josja Graafland; Hubertus Eussen; Hannie Douben; Annelies de Klein; Marco Onofrj; Vincenzo Bonifati
Journal:  Parkinsonism Relat Disord       Date:  2015-06-09       Impact factor: 4.891

7.  AMPA receptor subunit GluR1 (GluA1) serine-845 site is involved in synaptic depression but not in spine shrinkage associated with chemical long-term depression.

Authors:  Kaiwen He; Angela Lee; Lihua Song; Patrick O Kanold; Hey-Kyoung Lee
Journal:  J Neurophysiol       Date:  2011-02-09       Impact factor: 2.714

8.  α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation.

Authors:  Jacqueline Burré; Manu Sharma; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-22       Impact factor: 11.205

Review 9.  Phenotypic spectrum of alpha-synuclein mutations: New insights from patients and cellular models.

Authors:  Simona Petrucci; Monia Ginevrino; Enza Maria Valente
Journal:  Parkinsonism Relat Disord       Date:  2015-08-18       Impact factor: 4.891

10.  Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro.

Authors:  Jacqueline Burré; Manu Sharma; Theodoros Tsetsenis; Vladimir Buchman; Mark R Etherton; Thomas C Südhof
Journal:  Science       Date:  2010-08-26       Impact factor: 47.728

View more
  19 in total

1.  Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease.

Authors:  Milos Stanojlovic; Jean Pierre Pallais; Michael K Lee; Catherine M Kotz
Journal:  Mol Brain       Date:  2019-10-30       Impact factor: 4.041

Review 2.  Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Authors:  Phuong H Nguyen; Ayyalusamy Ramamoorthy; Bikash R Sahoo; Jie Zheng; Peter Faller; John E Straub; Laura Dominguez; Joan-Emma Shea; Nikolay V Dokholyan; Alfonso De Simone; Buyong Ma; Ruth Nussinov; Saeed Najafi; Son Tung Ngo; Antoine Loquet; Mara Chiricotto; Pritam Ganguly; James McCarty; Mai Suan Li; Carol Hall; Yiming Wang; Yifat Miller; Simone Melchionna; Birgit Habenstein; Stepan Timr; Jiaxing Chen; Brianna Hnath; Birgit Strodel; Rakez Kayed; Sylvain Lesné; Guanghong Wei; Fabio Sterpone; Andrew J Doig; Philippe Derreumaux
Journal:  Chem Rev       Date:  2021-02-05       Impact factor: 60.622

Review 3.  Oxidative stress factors in Parkinson's disease.

Authors:  Jolanta Dorszewska; Marta Kowalska; Michał Prendecki; Thomas Piekut; Joanna Kozłowska; Wojciech Kozubski
Journal:  Neural Regen Res       Date:  2021-07       Impact factor: 5.135

4.  Erythrocytic α-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson's disease pathogenesis.

Authors:  Lifu Sheng; Tessandra Stewart; Dishun Yang; Eric Thorland; David Soltys; Patrick Aro; Tarek Khrisat; Zhiying Xie; Na Li; Zongran Liu; Chen Tian; Matthew Bercow; Junichi Matsumoto; Cyrus P Zabetian; Elaine Peskind; Joseph F Quinn; Min Shi; Jing Zhang
Journal:  Acta Neuropathol Commun       Date:  2020-07-08       Impact factor: 7.801

5.  Introduction of Tau Oligomers into Cortical Neurons Alters Action Potential Dynamics and Disrupts Synaptic Transmission and Plasticity.

Authors:  Emily Hill; Thomas K Karikari; Kevin G Moffat; Magnus J E Richardson; Mark J Wall
Journal:  eNeuro       Date:  2019-10-15

6.  Chemogenetic Modulation of Orexin Neurons Reverses Changes in Anxiety and Locomotor Activity in the A53T Mouse Model of Parkinson's Disease.

Authors:  Milos Stanojlovic; Jean Pierre Pallais; Catherine M Kotz
Journal:  Front Neurosci       Date:  2019-07-30       Impact factor: 4.677

7.  Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α-synucleinopathy.

Authors:  Balvindar Singh; Ana Covelo; Héctor Martell-Martínez; Carmen Nanclares; Mathew A Sherman; Emmanuel Okematti; Joyce Meints; Peter J Teravskis; Christopher Gallardo; Alena V Savonenko; Michael A Benneyworth; Sylvain E Lesné; Dezhi Liao; Alfonso Araque; Michael K Lee
Journal:  Acta Neuropathol       Date:  2019-06-06       Impact factor: 17.088

Review 8.  Alpha-Synuclein and LRRK2 in Synaptic Autophagy: Linking Early Dysfunction to Late-Stage Pathology in Parkinson's Disease.

Authors:  Giulia Lamonaca; Mattia Volta
Journal:  Cells       Date:  2020-04-30       Impact factor: 6.600

9.  α-Synuclein A53T Binds to Transcriptional Adapter 2-Alpha and Blocks Histone H3 Acetylation.

Authors:  Ji-Yeong Lee; Hanna Kim; Areum Jo; Rin Khang; Chi-Hu Park; Soo-Jeong Park; Eunsang Kwag; Joo-Ho Shin
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

10.  Orientation of neurites influences severity of mechanically induced tau pathology.

Authors:  Nicholas J Braun; Dezhi Liao; Patrick W Alford
Journal:  Biophys J       Date:  2021-07-20       Impact factor: 3.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.